Macrogenics takes another shot at a novel immune checkpoint
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
Better late than never for Boehringer in Covid-19
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Lilly moves to stack the deck for donanemab
Attempts to improve the Alzheimer’s disease project’s chance of success are understandable, but the market has moved on for now.
AD/PD 2021 – Donanemab has much still to prove
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Roche and Vir add to the conflicting Covid-19 data
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
The US FDA gets tough
Tecentriq follows Opdivo, Imfinzi and Keytruda in having a US approved use knocked out.
Glaxo fails to win an Oscar
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
